Publikation: Blood cytokine response of low-dose molgramostim (rhGM-CSF)-treated patients
Dateien
Datum
Autor:innen
Herausgeber:innen
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
URI (zitierfähiger Link)
DOI (zitierfähiger Link)
Internationale Patentnummer
Link zur Lizenz
Angaben zur Forschungsförderung
Projekt
Open Access-Veröffentlichung
Sammlungen
Core Facility der Universität Konstanz
Titel in einer weiteren Sprache
Publikationstyp
Publikationsstatus
Erschienen in
Zusammenfassung
We examined leukocyte counts and ex vivo cytokine response of whole blood to lipopolysaccharide (LPS) or lipoteichoic acid (LTA) in patients under low-dose molgramostim therapy. Patients were injected subcutaneously daily for ten days with 1 μg/kg (n=9) or 2 μg/kg (n=14) molgramostim. Leukocytosis was observed in all patients, but only the eosinophil fraction was significantly increased in relation to other leukocyte populations. Ex vivo IFN-γ release was decreased and IL-10 and IL-1ra secretion were increased in response to LPS or LTA. Thus, in non-neutropenic patients, leukocytosis can already be initiated by low doses of molgramostim. The ex vivo cytokine data suggest that these doses prime blood towards a systemic anti-inflammatory response.
Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
Schlagwörter
Konferenz
Rezension
Zitieren
ISO 690
HARTUNG, Thomas, Sonja von AULOCK, Marcus FREITAG, Stefan HÖXTERMANN, Markus STÜCKER, Klaus HOFFMANN, Peter ALTMEYER, Andrea KOTTKE, Albrecht WENDEL, 2000. Blood cytokine response of low-dose molgramostim (rhGM-CSF)-treated patients. In: Cytokine. 2000, 12(10), pp. 1570-1574. ISSN 1043-4666. Available under: doi: 10.1006/cyto.2000.0752BibTex
@article{Hartung2000Blood-8305, year={2000}, doi={10.1006/cyto.2000.0752}, title={Blood cytokine response of low-dose molgramostim (rhGM-CSF)-treated patients}, number={10}, volume={12}, issn={1043-4666}, journal={Cytokine}, pages={1570--1574}, author={Hartung, Thomas and Aulock, Sonja von and Freitag, Marcus and Höxtermann, Stefan and Stücker, Markus and Hoffmann, Klaus and Altmeyer, Peter and Kottke, Andrea and Wendel, Albrecht} }
RDF
<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/8305"> <foaf:homepage rdf:resource="http://localhost:8080/"/> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dc:creator>Aulock, Sonja von</dc:creator> <dc:creator>Altmeyer, Peter</dc:creator> <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/8305/1/2000HartungCytok_bearb.pdf"/> <dc:creator>Hartung, Thomas</dc:creator> <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/8305/1/2000HartungCytok_bearb.pdf"/> <dc:creator>Hoffmann, Klaus</dc:creator> <dcterms:issued>2000</dcterms:issued> <dc:language>eng</dc:language> <dc:creator>Freitag, Marcus</dc:creator> <dc:contributor>Altmeyer, Peter</dc:contributor> <dcterms:title>Blood cytokine response of low-dose molgramostim (rhGM-CSF)-treated patients</dcterms:title> <dc:creator>Höxtermann, Stefan</dc:creator> <dc:contributor>Hartung, Thomas</dc:contributor> <dc:contributor>Hoffmann, Klaus</dc:contributor> <bibo:uri rdf:resource="http://kops.uni-konstanz.de/handle/123456789/8305"/> <dc:creator>Kottke, Andrea</dc:creator> <dc:contributor>Freitag, Marcus</dc:contributor> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-03-24T17:42:33Z</dcterms:available> <dcterms:bibliographicCitation>First publ. in: Cytokine 12 (2000), 10, pp. 1570-1574</dcterms:bibliographicCitation> <dc:format>application/pdf</dc:format> <dc:rights>Attribution-NonCommercial-NoDerivs 2.0 Generic</dc:rights> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <dc:creator>Wendel, Albrecht</dc:creator> <dc:contributor>Stücker, Markus</dc:contributor> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-03-24T17:42:33Z</dc:date> <dc:contributor>Wendel, Albrecht</dc:contributor> <dc:creator>Stücker, Markus</dc:creator> <dcterms:rights rdf:resource="http://creativecommons.org/licenses/by-nc-nd/2.0/"/> <dc:contributor>Aulock, Sonja von</dc:contributor> <dc:contributor>Kottke, Andrea</dc:contributor> <dcterms:abstract xml:lang="eng">We examined leukocyte counts and ex vivo cytokine response of whole blood to lipopolysaccharide (LPS) or lipoteichoic acid (LTA) in patients under low-dose molgramostim therapy. Patients were injected subcutaneously daily for ten days with 1 μg/kg (n=9) or 2 μg/kg (n=14) molgramostim. Leukocytosis was observed in all patients, but only the eosinophil fraction was significantly increased in relation to other leukocyte populations. Ex vivo IFN-γ release was decreased and IL-10 and IL-1ra secretion were increased in response to LPS or LTA. Thus, in non-neutropenic patients, leukocytosis can already be initiated by low doses of molgramostim. The ex vivo cytokine data suggest that these doses prime blood towards a systemic anti-inflammatory response.</dcterms:abstract> <dc:contributor>Höxtermann, Stefan</dc:contributor> </rdf:Description> </rdf:RDF>